within Pharmacolibrary.Drugs.ATC.B;

model B03AA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 1.3833333333333334e-05,
    adminDuration  = 600,
    adminMass      = 325 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0038333333333333336,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03AA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ferrous sulfate is an iron supplement used to treat or prevent low blood levels of iron (such as those caused by anemia or during pregnancy). It is commonly prescribed for iron-deficiency anemia and is available in oral formulations. Ferrous sulfate is a well-established and widely used medication approved in many countries.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetics in healthy adults (non-pregnant, both sexes). PK parameters may vary in special populations (e.g., pregnant women, patients with gastrointestinal disease).</p><h4>References</h4><ol><li><p>Auerbach, M, et al., &amp; Tirnauer, JS (2025). Iron Deficiency in Adults: A Review. <i>JAMA</i> 333(20) 1813–1823. DOI:<a href=&quot;https://doi.org/10.1001/jama.2025.0452&quot;>10.1001/jama.2025.0452</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40159291/&quot;>https://pubmed.ncbi.nlm.nih.gov/40159291</a></p></li><li><p>Gómez-Ramírez, S, et al., &amp; Muñoz, M (2023). Sucrosomial. <i>Pharmaceuticals (Basel, Switzerland)</i> 16(6) –. DOI:<a href=&quot;https://doi.org/10.3390/ph16060847&quot;>10.3390/ph16060847</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37375794/&quot;>https://pubmed.ncbi.nlm.nih.gov/37375794</a></p></li><li><p>Lorenz, M, et al., &amp; Sunder-Plassmann, G (2004). Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. <i>American journal of kidney diseases : the official journal of the National Kidney Foundation</i> 43(6) 1098–1103. DOI:<a href=&quot;https://doi.org/10.1053/j.ajkd.2004.03.021&quot;>10.1053/j.ajkd.2004.03.021</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15168391/&quot;>https://pubmed.ncbi.nlm.nih.gov/15168391</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03AA07;
